Using of supersaturated oxygen delivery (SSO2 therapy) in patients with acute myocardial ischemia

Oxygen is the main participant in redox reactions in the body and its deficiency can lead to organ dysfunction. Thus, a decrease in blood flow in a certain region of the myocardium in patients with coronary heart disease can cause a heart attack. According to experimental studies, early reperfusion reduces infarct size, and clinical studies have shown that early effective reperfusion of the affected artery and prevention of re-occlusion is the basis for minimizing infarct size and mortality.

Timely performed percutaneous intervention in patients with acute myocardial infarction significantly reduced the mortality rate and the risk of heart failure. Despite the endovascular treatment effectiveness, there is still a need for additional methods of cardioprotection, reducing the area of myocardial infarction and preventing the development of heart failure and adverse left ventricular remodeling. Blood oxygen supersaturation (SSO₂ therapy) is one of the adjuvant methods of cardioprotection in the treatment of patients with acute myocardial ischemia.

This review describes possible mechanisms for implementing the cardioprotective effects of SSO2 therapy, technology and equipment necessary for the application of this technique. In addition, the results of experimental and clinical studies on SSO₂ therapy are consecrated. Of note, only one multicentre prospective randomized controlled trial with uniform randomization was performed. Thus, the use of this technology is limited by the use a commercial equipment.

1.